Sun Pharmaceutical Industries
Sun Pharmaceutical Industries Ltd., commonly known as Sun Pharma, is a leading global pharmaceutical company headquartered in India. Established in 1993, the company has grown to become one of the largest specialty generic pharmaceutical manufacturers in the world, with a strong presence in North America, Europe, and emerging markets. Sun Pharma focuses on a diverse range of therapeutic areas, including cardiology, psychiatry, neurology, and dermatology. Its core products encompass a wide array of generic medications, specialty pharmaceuticals, and over-the-counter products, distinguished by their high quality and affordability. The company has achieved significant milestones, including numerous product approvals and a robust pipeline of innovative therapies. With a commitment to research and development, Sun Pharma has positioned itself as a key player in the global pharmaceutical landscape, recognised for its excellence in manufacturing and a strong market presence.
DitchCarbon Score
How does Sun Pharmaceutical Industries's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sun Pharmaceutical Industries's score of 63 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sun Pharmaceutical Industries's reported carbon emissions
In 2024, Sun Pharmaceutical Industries reported total carbon emissions of approximately 45606000 kg CO2e for Scope 1, 67203000 kg CO2e for Scope 2, and 379788000 kg CO2e for Scope 3, resulting in a combined total of about 112809000 kg CO2e for Scope 1 and 2. This reflects a significant commitment to addressing climate change, as the company has set a target to achieve a 35% reduction in its Scope 1 and Scope 2 emissions by 2030, using 2020 as the baseline year. In 2023, the emissions were recorded at approximately 111175000 kg CO2e for Scope 1, 237766000 kg CO2e for Scope 2, and 357266000 kg CO2e for Scope 3, with a total of about 368844000 kg CO2e for Scope 1 and 2 combined. The company has consistently disclosed emissions data across all three scopes, demonstrating transparency in its sustainability efforts. Sun Pharmaceutical's climate commitments are aligned with industry standards, focusing on reducing absolute emissions and improving overall sustainability. The 35% reduction target for Scope 1 and Scope 2 emissions underscores the company's proactive approach to mitigating its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 77,616,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 2 | 377,728,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | - | - | 0,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sun Pharmaceutical Industries is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
